This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.



Martin B. Keller, M.D.

Published: January 1, 1997

Article Abstract
‘ ‹’ ‹

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Recent research has indicated a role for antidepressants in such diverse disorders as premenstrual dysphoric disorder, attention-deficit/hyperactivity disorder (ADHD), social phobia, obsessive-compulsive disorder (OCD), borderline personality disorder, and panic disorder. Since the newer serotonin selective reuptake inhibitors (SSRIs), venlafaxine, and nefazodone have a more benign side effect profile than the older tricyclics and monoamine oxidase inhibitors (MAOIs), controlled trials of the newer agents in many different disorders are under way. Preliminary evidence on efficacy, which ranges from randomized controlled trials that point strongly to efficacy to open-label studies with more tentative results, will be presented in this Supplement to The Journal of Clinical Psychiatry.’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 58

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...